FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with ...(ty and other litigation risks and enviro...),Health

Date:11/13/2008

ty and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2007, which was filed with the Securities and Exchange Commission on February 29, 2008. The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Read the full story at http://www.prweb.com/releases/vaginal_cream/premarin_vaginal/prweb1614152.htm

'/>"/>

Source: PRWeb Copyright©2008 Vocus, Inc. All rights reserved

3 GOOD

Page: 1 2 3 4
Related medicine news :

1. FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse
2. Pennsylvania Insurance Department Approves Launch of Senior Health Care Oversight Trust
3. US FDA Approves 30-Minute Onset of Action for Focalin(R) XR, Bringing Potential Benefits to ADHD Patients During Early Morning Period
4. FDA Approves New Indication for Hospiras Precedex (Dexmedetomidine HCL) Injection
5. Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million
6. Kaiser Permanente Approves $12 Million in Community Benefit Grants in Third Quarter of 2008
7. Congress Sets New Course for Lung Cancer Research; Approves $20 Million for New Defense Department Program
8. FDA Approves Nasacort AQ(R) Nasal Spray for Children Aged 2-5 years old
9. ClearWay Minnesota(SM) Board Approves New Officers
10. FDA approves first drug for Huntingtons disease
11. The California Board of Registered Nursing Approves Affiliations for Nursing Program in Glendale, California